GBS-NN/NN2 vaccine

Preclinical

GBS-NN/NN2 vaccine is one of 2 therapeutic programs targeting Streptococcus Agalactiae Infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Streptococcus Agalactiae InfectionActive, not recruiting

Streptococcus Agalactiae InfectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Streptococcus Agalactiae Infection

#DrugCompanyPhaseTrials

GBS-NN/NN2

MMinervax ApS

Preclinical

1 2

GBS-NN/NN2 vaccine

MMinervax ApS

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalActive, not recruiting

Streptococcus Agalactiae Infection

NCT06592586

Clinical

Trials by Indication[1]

Streptococcus Agalactiae Infection1 trial

A Follow-up Trial to Assess the Persistence of the Immune Response to the Group B Streptococcus Vaccine (GBS-NN/NN2) After a Primary Vaccination of Healthy Pregnant Women, and to Assess Safety, Reactogenicity, and Immunogenicity of the GBS-NN/NN2 Vaccine When Administered During Follow-Up as a 1 Booster Dose During a New Pregnancy

Active, not recruiting·MMinervax ApS·Preclinical·NCT06592586·137 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GBS-NN/NN2 vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for GBS-NN/NN2 vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Minervax ApS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: MMinervax ApS

GBS-NN/NN2 vaccine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Streptococcus Agalactiae Infection1 trial

References

Drug Info

Quick Facts

Related News